A Test in Focus

The new Phospholipase A2 Receptor Antibodies, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test can be used to help distinguish primary from secondary membranous nephropathy. However, it should not be used as a stand-alone test but an adjunct to other clinical information.

By Alyssa Frank • October 8, 2015

The new GRHPR Gene, Full Gene Analysis, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By brentwestra • September 9, 2015

The new Lipoprotein-Associated Phospholipase A2 Activity, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.

By brentwestra • July 28, 2015

The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.

By brentwestra • May 13, 2015

The new RAS/RAF Targeted Gene Panel by Next Generation Sequencing, Tumor, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. In this post, Dr. Ande Rumilla discusses the clinical significance, proper ordering scenarios, and the science behind the test.

By brentwestra • January 13, 2015

The new Histoplasma Antigen, Urine test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered in individuals suspected to be infected with Histoplasma capsulatum.

By brentwestra • August 22, 2014

A new dementia autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune dementia, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 30, 2014

A new encephalopathy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune encephalopathy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 21, 2014

A new epilepsy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune epilepsy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 10, 2014

A new Trichomonas vaginalis assay is now available. This test should be ordered in individuals suspected to be infected with Trichomonas vaginalis. View this post to watch a short three-minute video overview from Bobbi Pritt, M.D. and to view new test utilization pearls.

By Andy Tofilon • June 18, 2014

The new CALR Mutation Analysis, Myeloproliferative Neoplasm (MPN) assay is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered on patients with clinical suspicion of essential thrombocythemia or primary myelofibrosis.

By Andy Tofilon • May 12, 2014

This new gene panel cancer test helps tailor therapies to the individual patient based on the unique genomic signature of the patient’s tumor. This test scans specific regions in 50 genes known to affect tumor growth and response to therapies. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.

By Andy Tofilon • April 24, 2014

This new Mayo Clinic assay provides clinicians an accurate measurement of serum thyroglobulin in patients with known or suspected anti-thyroglobulin autoantibodies or heterophilic antibodies. View a quick overview of the test’s details and a five-minute video interview with Dr. Stefan Grebe.

By Kelley Luedke • April 8, 2014